Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: A multicenter, randomized, placebo-controlled thrial

Asian Pacific Journal of Allergy and Immunology

Volumn 26, Issue 2-3, 2008, Pages 105-112

  Tseng, Shih Hann ^a   Fu, Lin Shien ^b   Nong, Bao Ren ^c   Weng, Jyh Der ^a   Shyur, Shyh Dar ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FEXOFENADINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PLACEBO; SALBUTAMOL SULFATE; STALORAL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TOLERABILITY; EPISTAXIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOUTH ULCER; MULTICENTER STUDY; ORAL PARESTHESIA; PRICK TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT COURSE THERAPY; SKIN SENSITIVITY; SUBLINGUAL SWALLOW IMMUNOTHERAPY; TAIWAN;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ANIMALS; ANTIBODY FORMATION; ANTIGENS, DERMATOPHAGOIDES; CHILD; CLINICAL PROTOCOLS; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; NASAL OBSTRUCTION; RHINITIS, ALLERGIC, PERENNIAL; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME;

EID: 58149475502     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Zar HJ, Ehrlich RI, Workman L, Weinberg EG. The changing prevalence of asthma, allergic rhinitis and atopic eczema in African adolescents from 1995 to 2002. Pediatr Allergy Immunol 2007; 18: 560-5.
2. Hayden ML, Womack CR. Caring for patients with allergic rhinitis. J Am Acad Nurse Pract 2007; 19: 290-8.
3. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2004; 113: 635-42.
4. Frew AJ. Immunotherapy of allergic disease. J Allergy Clin Immunol 2003; 111: S712-9.
5. Stewart GE, 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90: 567-75.
6. Passalacqua G, Canonica GW. Alternative routes for allergen-specific immunotherapy. J Invest Allergol Clin Immunol 1996; 6: 81-7.
7. Chang YC, Hsieh KH. The study of house dust mites in Taiwan. Ann Allergy 1989; 62: 101-6.
8. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual swallow immunotherapy in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000; 55: 369-75.
9. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997; 8: 21-7.
10. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol 1990; 18: 277-84.
11. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136: 287-94.
12. Passalacqua G, Durham SR, Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119: 881-91.
13. Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008; 100: 256-63
14. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151-65.
15. Kolbe L, Heusser CH, Kolsch E. Isotype-associated recognition of allergen epitopes and its modulation by antigen dose. Immunology 1995; 84: 285-9.
16. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen- specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophile histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198-208.
17. Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 2007; 25: 957-64.
18. Flicker S. Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003; 132: 13-24.
19. Djurup R. The subclass nature and clinical significance of the IgG antibody response in subjects undergoing allergen-specific immunotherapy. Allergy 1985; 40: 469-86.
20. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86: 521-31.
21. Lu FM, Chou CC, Chiang BL, Hsieh KH. Immunologic changes during immunotherapy in asthmatic children: increased IL-13 and allergen-specific IgG4 antibody levels. Ann Allergy Asthma Immunol 1998; 80: 419-23.
22. Un KL, Wang SY, Hsieh KH. Analysis of house dust mite-specific IgE, IgG4, and IgG antibodies during immunotherapy in asthmatic children. Ann Allergy 1991; 67: 63-9.
23. Van Neerven RJ, Wikborg T, Lund G. Blocking antibodies induced by specific allergy vaccination prevents the activation of CD4(+) T cells by inhibiting serum IgE-facilitated allergen presentation. J Immunol 1999; 163: 2944-52.
24. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Invest Allergol Clin Immunol 1995; 5: 25- 30.
25. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual- swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104: 425-32.
26. Lima MT, Wilson D, Pitkin L. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis:randomized controlled trial. Clin Exp Allergy 2002; 32: 507-14.
27. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121: 229-34.